title: A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo.
abstract: Expression of fibroblast growth factor (FGF)-inducible 14 (Fn14), a member of the tumor necrosis factor receptor superfamily, is typically low in healthy adult organisms, but strong Fn14 expression is induced in tissue injury and tissue remodeling. High Fn14 expression is also observed in solid tumors, which is why this receptor is under consideration as a therapeutic target in oncology. Here, we describe various novel mouse-human cross-reactive llama-derived recombinant Fn14-specific antibodies (5B6, 18D1, 4G5) harboring the human IgG1 Fc domain. In contrast to recombinant variants of the established Fn14-specific antibodies PDL192 and P4A8, all three llama-derived antibodies efficiently bound to the W42A and R56P mutants of human Fn14. 18D1 and 4G5, but not 5B6, efficiently blocked TNF-like weak inducer of apoptosis(TWEA K) binding at low concentrations (0.2–2 μg/ml). Oligomerization and Fcγ receptor (FcγR) binding converted all antibodies into strong Fn14 agonists. Variants of 18D1 with enhanced and reduced antibody-dependent cell-mediated cytotoxicity (ADCC) activity were further analyzed in vivo with respect to their effect on metastasis. In a xenogeneic model using human colon carcinoma cancer cells, both antibody variants were effective in reducing metastasis to the liver. In contrast, only the 18D1 variant with enhanced ADCC activity, but not its ADCC-defective counterpart, suppressed lung metastasis in the RE NCA model. In sum, this suggests that Fn14 targeting might primarily act by triggering of antibody effector functions, but also by blockade of TWEA K-Fn14 interaction in some cases
authors.forename: Johannes
authors.initials: J
authors.lastname: Trebing
authors.forename: Isabell
authors.initials: I
authors.lastname: Lang
authors.forename: Martin
authors.initials: M
authors.lastname: Chopra
authors.forename: Steffen
authors.initials: S
authors.lastname: Salzmann
authors.forename: Mahan
authors.initials: M
authors.lastname: Moshir
authors.forename: Karen
authors.initials: K
authors.lastname: Silence
authors.forename: Simone S
authors.initials: SS
authors.lastname: Riedel
authors.forename: Daniela
authors.initials: D
authors.lastname: Siegmund
authors.forename: Andreas
authors.initials: A
authors.lastname: Beilhack
authors.forename: Christoph
authors.initials: C
authors.lastname: Otto
authors.forename: Harald
authors.initials: H
authors.lastname: Wajant
mesh_terms: D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002161:Camelids, New World / Q000276:immunology*; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D057809:HEK293 Cells; D064593:Heterografts; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D051379:Mice; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000276:immunology*; D009368:Neoplasm Transplantation; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology*; D000074050:TWEAK Receptor; D023041:Xenograft Model Antitumor Assays
chemical_list: D000912:Antibodies, Neoplasm; D009363:Neoplasm Proteins; D018124:Receptors, Tumor Necrosis Factor; C000613297:TNFRSF12A protein, human; D000074050:TWEAK Receptor; C000613299:Tnfrsf12a protein, mouse